Filing summary
Important identity discrepancy: The request identifies Enveric Biosciences, Inc., but the supplied 10-Q is for Spatializer Audio Laboratories, Inc. This summary reflects the filing text, which reports the quarter ended March 31, 2012.
Business context and reporting period
Spatializer reported that it ceased commercial operations in 2006 and did not expect significant operations until it completed a merger, acquisition, business combination, or other financial transaction. The filing describes the company as a shell company. Interim financial statements are unaudited.
Financial results and position
| Metric | Q1 2012 / March 31, 2012 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q1 2011 |
| General and administrative expense | $4,045 | $11,084 in Q1 2011 |
| Net loss | $4,045 | $11,084 in Q1 2011 |
| Cash and cash equivalents | $6,086 | $18,231 at December 31, 2011 |
| Total assets | $10,305 | $22,450 at December 31, 2011 |
| Current liabilities | $9,795 | $17,895 at December 31, 2011 |
| Working capital / stockholders’ equity | $510 | $4,555 at December 31, 2011 |
| Net cash used in operating activities | $12,145 | $16,971 used in Q1 2011 |
The filing does not report revenue-based margins. No debt balance is presented; liabilities shown are accounts payable and accrued liabilities. Cash declined by $12,145 during the quarter, primarily due to operating expenses and payments of liabilities. The filing states that cash reserves were not sufficient to meet obligations for more than 3–6 months without additional capital and that the company had no current source of future cash flow.
Changes versus the prior comparable period
- Revenue remained at zero.
- Net loss and operating expenses improved to $4,045 from $11,084.
- Operating cash use narrowed to $12,145 from $16,971; unlike Q1 2011, the company reported no shareholder loan proceeds in Q1 2012.
- Weighted average shares outstanding increased to 12,142,000 from 6,500,000; reported loss per share was $0.00 in both periods.
- Compared with December 31, 2011, cash fell by $12,145 and working capital declined by $4,045.
Outlook, risks, and unusual items
- Management intended to maintain the company as a public entity and pursue a business combination or other transaction; it did not expect significant operations before one was completed.
- The filing states that significant operating losses raise substantial doubt about the company’s ability to continue as a going concern. The financial statements contain no adjustments for the outcome of this uncertainty.
- Management believed liquidity could be maintained in the short term, but warned that additional capital would be needed within 3–6 months. No financing commitment or specific funding plan is disclosed in the supplied text.
- The company reported approximately $9.5 million of federal net operating loss carryforwards, generally available through 2031, subject to an approximately $1 million annual limitation and potential ownership-change restrictions.
- No material subsequent events were reported. The company said no legal proceedings were expected to have a material adverse effect, while noting the inherent uncertainty of litigation.
- Management concluded that disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Confirm the issuer and filing: the supplied document names Spatializer Audio Laboratories, Inc., not Enveric Biosciences, Inc.
- Verify the reported cash, liabilities, working capital, and cash runway, including the filing’s statement that reserves cover only 3–6 months without new capital.
- Assess whether the company secured financing or completed a business combination after the reporting date; the filing reports no material subsequent event through its disclosure date.
- Review the going-concern warning and the restrictions that may limit use of the reported tax loss carryforwards.